Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10653719 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
US10933089 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
US10905713 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
US11510942 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
US10905714 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
US10918662 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
US10478453 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
US10583155 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
US10912795 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
US11510941 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Mar, 2039
(14 years from now) | |
US11045438 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(14 years from now) | |
US10543186 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(14 years from now) | |
US10493051 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(14 years from now) | |
US10702490 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(14 years from now) |
Nouress is owned by Baxter Hlthcare Corp.
Nouress contains Cysteine Hydrochloride.
Nouress has a total of 14 drug patents out of which 0 drug patents have expired.
Nouress was authorised for market use on 13 December, 2019.
Nouress is available in solution;intravenous dosage forms.
Nouress can be used as method of using l-cysteine in an admixture for treating patients needing parenteral nutrition, method of intravenously administering a diluted cysteine hydrochloride solution to a neonate in need thereof.
The generics of Nouress are possible to be released after 15 March, 2039.
Drugs and Companies using
CYSTEINE HYDROCHLORIDE ingredient